Study of IMO-2055 in Metastatic or Locally Recurrent Clear Cell Renal Carcinoma

Browse trials for

• Carcinoma 6,741
• Carcinoma, Renal Cell 1,965
• Kidney Neoplasms 956

Keywords

• renal
• cell
• renal carcinoma
• metastatic
• recurrent
• treatment naive

Carcinoma

6,741 studies on the registry are indexed under Carcinoma; 1,161 are open to participants now.

This study's enrollment of 92 is above the median of 45 across 5,170 interventional studies indexed under Carcinoma.

Lead sponsor

Idera Pharmaceuticals, Inc. is the lead sponsor of 13 studies on the registry; none are open to participants now.

Study arms

• Active comparator
  Previous treatment, 0.16mg/kg

  Patients will have clear cell renal carcinoma with previous treatment. Patients will receive weekly SC injections of IMO-2055 at a dose of 0.16mg/kg

  Drug: IMO-2055

• Active comparator
  Previous treatment, 0.64mg/kg

  Patients will have clear cell renal carcinoma with previous treatment. Patients will receive weekly SC injections of IMO-2055 at a dose of 0.64mg/kg

  Drug: IMO-2055

• Active comparator
  Treatment Naive, 0.16mg/kg

  Patients will have clear cell renal carcinoma without previous treatment. Patients will receive weekly SC injections of IMO-2055 at a dose of 0.16mg/kg

  Drug: IMO-2055

• Active comparator
  Treatment Naive, 0.64mg/kg

  Patients will have clear cell renal carcinoma without previous treatment. Patients will receive weekly SC injections of IMO-2055 at a dose of 0.64mg/kg

  Drug: IMO-2055

Interventions

• DrugIMO-2055

  immunostimulatory oligonucleotide

Primary outcomes

1. Best Response by RECIST v1.0

   Best overall objective (i.e., radiological) response by RECIST v1.0 for target lesions: Complete Response (CR): Disappearance of all target lesions; Partial Response (PR): At least a 30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR in patients with clear cell metastatic or locally recurrent renal cell carcinoma treated with IMO-2055.

   Time frame: From start of treatment every 8 weeks (every 2 cycles), 1 month post-treatment, then every 3 months (up to 1 year) until documented disease progression or initiation of an alternative therapeutic treatment regimen.

Secondary outcomes

1. Number of Participants With Treatment-emergent Adverse Events (TEAEs) by National Cancer Institute (NCI) Grade/Severity

   Number of patients with Treatment-emergent adverse events (TEAEs) by National Cancer Institute (NCI) grade/severity that began on or after the date of the first injection of study drug or worsened in severity or frequency after study drug was administered.

   Time frame: From start of treatment through one month after the end of study visit (up to 28 weeks)

2. Duration of Response by RECIST v1.0

   Time in days from the date of the first response by RECIST v1.0 to documented disease progression or death from any cause.

   Time frame: Every 8 weeks (2 cycles) from first response to documented disease progression during treatment, 1 month post-treatment, then every 3 months (up to 1 year) until documented disease progression or initiation of an alternative therapeutic treatment regimen.

3. Overall Survival at 1 Year

   Overall survival is defined as (date of death +1 - date of randomization). Patients without an event (death) during treatment or follow-up will have their date censored on the last visit the patient was known to be alive.

   Time frame: From date of randomization until the date of progression or date of death from any cause, whichever came first, asses up to 1 year after the last dose of study drug.

4. Time to Disease Progression.

   Time between the date of randomization to the Study Day of documented disease progression (an increase in tumor burden of at least 20%, appearance of new lesions, or unequivocal progression of non-measurable disease) or death (whichever comes first) by RECIST v1.0. Patients who had not progressed at last disease assessment, but whose progression status was unknown at the date last known alive, date of death, or date of study exit (whichever comes first), had event time censored at the date of last assessment. Patients who did not die and did not progress during treatment or follow-up had their event time censored on the last contact date.

   Time frame: Every 8 weeks (2 cycles) during the study and every 3 months for 1 year until documented disease progression

Baseline characteristics